1
|
Takeuchi H. The importance of early and proactive use of long-acting injectable antipsychotics in the management of schizophrenia. Int Clin Psychopharmacol 2023; 38:182-183. [PMID: 36866848 DOI: 10.1097/yic.0000000000000463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Affiliation(s)
- Hiroyoshi Takeuchi
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
2
|
Reymann S, Schoretsanitis G, Egger ST, Mohonko A, Kirschner M, Vetter S, Homan P, Seifritz E, Burrer A. Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland. J Pers Med 2022; 12:jpm12030441. [PMID: 35330441 PMCID: PMC8955244 DOI: 10.3390/jpm12030441] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Revised: 03/05/2022] [Accepted: 03/09/2022] [Indexed: 01/13/2023] Open
Abstract
Long-acting injectable antipsychotics (LAIs) offer many benefits to patients with schizophrenia spectrum disorder (SSD). They are used with very different frequencies due to questions of eligibility or patients and prescribers’ attitudes towards LAI use. We assessed the prescribing rates of LAIs in a large academic psychiatric hospital with a public service mandate in Switzerland and compared them with other countries and health care systems. To our knowledge, this study is the first to investigate inpatient LAI use in Europe. Medical records of all patients diagnosed with SSD discharged from the Clinic of Adult Psychiatry of the University Hospital of Psychiatry Zurich over a 12 month period from January to December 2019 were evaluated regarding the prescribed antipsychotics at the time of discharge. The rates of use of LAIs among all patients and among patients receiving LAI-eligible antipsychotic substances were assessed retrospectively. We assessed records of 885 patients with SSD. Among all cases, 13.9% received an LAI. Among patients who received antipsychotic medication that was eligible for LAI use (n = 434), 28.1% received an agent as an LAI. LAI use included paliperidone palmitate (69.9%), aripiprazole monohydrate (14.6%), risperidone (4.9%) and first-generation LAIs (9.8%). Compared to international frequencies of LAI administration, the prescription rate of LAIs in SSD patients was low. Further studies will evaluate patient- and prescriber-related reasons for this low rate.
Collapse
Affiliation(s)
- Stephan Reymann
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, 8032 Zurich, Switzerland; (S.R.); (G.S.); (S.T.E.); (A.M.); (M.K.); (S.V.); (P.H.); (E.S.)
| | - Georgios Schoretsanitis
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, 8032 Zurich, Switzerland; (S.R.); (G.S.); (S.T.E.); (A.M.); (M.K.); (S.V.); (P.H.); (E.S.)
| | - Stephan T. Egger
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, 8032 Zurich, Switzerland; (S.R.); (G.S.); (S.T.E.); (A.M.); (M.K.); (S.V.); (P.H.); (E.S.)
| | - Alexey Mohonko
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, 8032 Zurich, Switzerland; (S.R.); (G.S.); (S.T.E.); (A.M.); (M.K.); (S.V.); (P.H.); (E.S.)
| | - Matthias Kirschner
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, 8032 Zurich, Switzerland; (S.R.); (G.S.); (S.T.E.); (A.M.); (M.K.); (S.V.); (P.H.); (E.S.)
| | - Stefan Vetter
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, 8032 Zurich, Switzerland; (S.R.); (G.S.); (S.T.E.); (A.M.); (M.K.); (S.V.); (P.H.); (E.S.)
| | - Philipp Homan
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, 8032 Zurich, Switzerland; (S.R.); (G.S.); (S.T.E.); (A.M.); (M.K.); (S.V.); (P.H.); (E.S.)
- Neuroscience Center Zurich, University of Zurich, 8057 Zurich, Switzerland
| | - Erich Seifritz
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, 8032 Zurich, Switzerland; (S.R.); (G.S.); (S.T.E.); (A.M.); (M.K.); (S.V.); (P.H.); (E.S.)
| | - Achim Burrer
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, 8032 Zurich, Switzerland; (S.R.); (G.S.); (S.T.E.); (A.M.); (M.K.); (S.V.); (P.H.); (E.S.)
- Correspondence:
| |
Collapse
|